News and events
- All
- Events
- Press releases
- Publications
All
- All
- Events
- Press releases
- Publications
ExeVir Bio Announces New Publication from VIB Scientists Showing Potent and Broad Neutralizing Activity and Infection Protection against SARS-COV-2 and related coronaviruses
ExeVir, which is developing single domain antibody therapies providing broad
March 9, 2021
Read More
ExeVir Bio Appoints Michel Kazatchkine and Stef Heylen to the Board of Directors
ExeVir, which is developing nanobody therapies providing broad protection against
November 3, 2020
Read More
ExeVir Bio to Accelerate Development of New Treatment Conferring Broad Protection Against Covid-19
ExeVir Bio announces today a first closing of a EUR23
July 28, 2020
Read More
Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies
Using llamas immunized with prefusionstabilized betacoronavirus spike proteins, Wrapp et
July 24, 2020
Read More